Percheron Therapeutics Limited

As of June 30, 2026, Percheron Therapeutics Limited carries a market capitalization of 3.04M, placing it among publicly traded companies globally. Its enterprise value stands at 607,013.71, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Percheron Therapeutics Limited's next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Percheron Therapeutics Limited has 1.52B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Percheron Therapeutics Limited maintains a current ratio of 7.64, meaning it holds 7.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.37, indicating conservative leverage, while an interest coverage ratio of -352.03 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Percheron Therapeutics Limited posted a negative return on equity (ROE) of -54.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -46.39, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Percheron Therapeutics Limited's stock has declined approximately 53.33% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -3.27M, while operating income came in at -3.40M.

As of June 30, 2026, Percheron Therapeutics Limited holds 2.45M in cash and equivalents against 16,831.20 in total debt, resulting in a net debt position of -2.45M. Total book value stands at 4.56M, with working capital of 2.78M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -38.48, meaning Percheron Therapeutics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Percheron Therapeutics Limited's most recent stock split took place on March 19, 2026 with a 75:77 split ratio.